TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T. Tagawa, Petros Grivas, Manojkumar Bupathi et al.|Journal of Clinical Oncology|2021Cited by 530
FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†Bas W.G. van Rhijn, Tahlita C.M. Zuiverloon, Laura S. Mertens et al.|European Urology|2020Cited by 89
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patientsLaura S. Mertens, Bas W.G. van Rhijn, Francesco Claps et al.|Urologic Oncology Seminars and Original Investigations|2021Cited by 39
AcSé immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer typesAurélien Marabelle, Christophe Massard, Sylvie Chevret et al.|Annals of Oncology|2018Cited by 0